1
|
Laiton-Donato K, Ávila-Robayo P, Páez-Martinez A, Benjumea-Nieto P, Usme-Ciro JA, Pinzón-Nariño N, Giraldo I, Torres-Castellanos D, Nakazawa Y, Patel N, Wilkins K, Li Y, Davidson W, Burgado J, Satheshkumar PS, Styczynski A, Mauldin MR, Gracia-Romero M, Petersen BW. Progressive Vaccinia Acquired through Zoonotic Transmission in a Patient with HIV/AIDS, Colombia. Emerg Infect Dis 2021; 26:601-605. [PMID: 32091366 PMCID: PMC7045850 DOI: 10.3201/eid2603.191365] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
In March 2015, a patient in Colombia with HIV/AIDS was hospitalized for disseminated ulcers after milking cows that had vesicular lesions on their udders. Vaccinia virus was detected, and the case met criteria for progressive vaccinia acquired by zoonotic transmission. Adherence to an optimized antiretroviral regimen resulted in recovery.
Collapse
|
2
|
Narita F, Wang Z, Kurita H, Li Z, Shi Y, Jia Y, Soutis C. A Review of Piezoelectric and Magnetostrictive Biosensor Materials for Detection of COVID-19 and Other Viruses. Adv Mater 2021; 33:e2005448. [PMID: 33230875 PMCID: PMC7744850 DOI: 10.1002/adma.202005448] [Citation(s) in RCA: 73] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 09/19/2020] [Indexed: 05/19/2023]
Abstract
The spread of the severe acute respiratory syndrome coronavirus has changed the lives of people around the world with a huge impact on economies and societies. The development of wearable sensors that can continuously monitor the environment for viruses may become an important research area. Here, the state of the art of research on biosensor materials for virus detection is reviewed. A general description of the principles for virus detection is included, along with a critique of the experimental work dedicated to various virus sensors, and a summary of their detection limitations. The piezoelectric sensors used for the detection of human papilloma, vaccinia, dengue, Ebola, influenza A, human immunodeficiency, and hepatitis B viruses are examined in the first section; then the second part deals with magnetostrictive sensors for the detection of bacterial spores, proteins, and classical swine fever. In addition, progress related to early detection of COVID-19 (coronavirus disease 2019) is discussed in the final section, where remaining challenges in the field are also identified. It is believed that this review will guide material researchers in their future work of developing smart biosensors, which can further improve detection sensitivity in monitoring currently known and future virus threats.
Collapse
Affiliation(s)
- Fumio Narita
- Department of Frontier Sciences for Advanced EnvironmentGraduate School of Environmental StudiesTohoku UniversityAoba‐yama 6‐6‐02Sendai980‐8579Japan
| | - Zhenjin Wang
- Department of Materials ProcessingGraduate School of EngineeringTohoku UniversityAoba‐yama 6‐6‐02Sendai980‐8579Japan
| | - Hiroki Kurita
- Department of Frontier Sciences for Advanced EnvironmentGraduate School of Environmental StudiesTohoku UniversityAoba‐yama 6‐6‐02Sendai980‐8579Japan
| | - Zhen Li
- College of Automation EngineeringNanjing University of Aeronautics and Astronautics29 Jiangjun AvenueNanjing211106China
| | - Yu Shi
- Department of Mechanical EngineeringUniversity of ChesterThornton Science Park, Pool LaneChesterCH2 4NUUK
| | - Yu Jia
- School of Engineering and Applied ScienceAston UniversityBirminghamB4 7ETUK
| | - Constantinos Soutis
- Aerospace Research InstituteThe University of ManchesterOxford RoadManchesterM13 9PLUK
| |
Collapse
|
3
|
Robertson J, Susong J, Wong EB. Smallpox vaccine complications: the dermatologist's role in diagnosis and management. Cutis 2018; 101:87-90. [PMID: 29554163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
In 2002, the United States implemented a new program for smallpox vaccinations among military personnel using a live vaccinia virus product. Approximately 2.4 million US military service members and health care workers have since been inoculated, with considerable numbers experiencing adverse reactions. Military dermatologists are at the forefront of describing and treating these reactions, from relatively benign generalized vaccinia (GV) and erythema multiforme (EM) to more severe progressive vaccinia (PV) and eczema vaccinatum (EV). A wide range of providers, including civilian dermatologists and primary care providers, also may see such reactions and must be aware of the spectrum of vaccine reactions. Given current world instability (eg, threats of nuclear war, rise of authoritarian regimes) and concerns for bioterrorism attacks, the smallpox vaccine program likely will continue indefinitely. As the brisk military deployment tempo continues, a larger population of new vaccinees will yield more cutaneous reactions and diagnostic challenges.
Collapse
|
4
|
Abstract
BACKGROUND Emerging and understudied pathogens often lack information that most commonly used analytical tools require, such as negative controls or baseline data; thus, new analytical strategies are needed to analyze transmission patterns and drivers of disease emergence. Zoonotic infections with Vaccinia virus (VACV) were first reported in Brazil in 1999, VACV is an emerging zoonotic Orthopoxvirus, which primarily infects dairy cattle and farmers in close contact with infected cows. Prospective studies of emerging pathogens could provide critical data that would inform public health planning and response to outbreaks. By using the location of 87-recorded outbreaks and publicly available bioclimatic data, we demonstrate one such approach. Using an ecological niche model (ENM) algorithm, we identify the environmental conditions under which VACV outbreaks have occurred, and determine additional locations in two affected countries that may be susceptible to transmission. Further, we show how suitability for the virus responds to different levels of various environmental factors and highlight the most important factors in determining its transmission. METHODS A literature review was performed and the geospatial coordinates of 87 molecularly confirmed VACV outbreaks in Brazil were identified. An ENM was generated using MaxENT software by combining principal component analysis results of 19 bioclim spatial layers, and 25 randomly selected subsets of the original list of 87 outbreaks. RESULTS The final ENM predicted all areas where Brazilian outbreaks occurred, one out of five of the Colombian outbreak regions and identified new regions within Brazil that are suitable for transmission based on bioclimatic factors. Further, the most important factors in determining transmission suitability are precipitation of the wettest quarter, annual precipitation, mean temperature of the coldest quarter and mean diurnal range. CONCLUSION The analyses here provide a means by which to study patterns of an emerging infectious disease and identify regions that are potentially suitable for its transmission, in spite of the paucity of high-quality critical data. Policy and methods for the control of infectious diseases often use a reactionary model, addressing diseases only after significant impact on human health has ensued. The methodology used in the present work allows the identification of areas where disease is likely to appear, which could be used for directed intervention.
Collapse
Affiliation(s)
- Claire A. Quiner
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology (DHCPP), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), US Centers for Disease Control and Prevention, Atlanta, GA USA
| | - Yoshinori Nakazawa
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology (DHCPP), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), US Centers for Disease Control and Prevention, Atlanta, GA USA
| |
Collapse
|
5
|
Peres MG, Barros CB, Appolinário CM, Antunes JMAP, Mioni MSR, Bacchiega TS, Allendorf SD, Vicente AF, Fonseca CR, Megid J. Dogs and Opossums Positive for Vaccinia Virus during Outbreak Affecting Cattle and Humans, São Paulo State, Brazil. Emerg Infect Dis 2016; 22:271-3. [PMID: 26812352 PMCID: PMC4734541 DOI: 10.3201/eid2202.140747] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
During a vaccinia virus (VACV) outbreak in São Paulo State, Brazil, blood samples were collected from cows, humans, other domestic animals, and wild mammals. Samples from 3 dogs and 3 opossums were positive for VACV by PCR. Results of gene sequencing yielded major questions regarding other mammalian species acting as reservoirs of VACV.
Collapse
|
6
|
Abstract
Vaccinia virus is a member of the orthopoxvirus group, to which also belongs variola virus, one of the most hazardous pathogens known to man. To establish a model system to detect orthopoxviruses, a vaccinia oligonucleotide microarray is designed, produced and tested. Vaccinia virus is used to test the prepared microarrays. The virus DNA samples in different propagation phases are extracted and hybridised with the oligonucleotide microarray. The results showed that the oligonucleotide microarray can detect vaccinia virus with high specificity and sensitivity.
Collapse
Affiliation(s)
- M Wenli
- Institute of Molecular Biology, First Uniform Medical University, Guangzhou 510515, PR China.
| | | | | | | |
Collapse
|
7
|
Ruehe B, Capaul R, Müller N, Sax H, Hasse B. [What is your diagnosis?]. Praxis (Bern 1994) 2015; 104:893-895. [PMID: 26286493 DOI: 10.1024/1661-8157/a002110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- Bettina Ruehe
- 1 Institut für Medizinische Virologie, Universität Zürich
| | | | | | | | | |
Collapse
|
8
|
Riyesh T, Karuppusamy S, Bera BC, Barua S, Virmani N, Yadav S, Vaid RK, Anand T, Bansal M, Malik P, Pahuja I, Singh RK. Laboratory-acquired buffalopox virus infection, India. Emerg Infect Dis 2014; 20:324-6. [PMID: 24447599 PMCID: PMC3901488 DOI: 10.3201/eid2002.130358] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
9
|
Webber BJ, Montgomery JR, Markelz AE, Allen KC, Hunninghake JC, Ritchie SA, Pawlak MT, Johnston LA, Oliver TA, Winterton BS. Spread of vaccinia virus through shaving during military training, Joint Base San Antonio-Lackland, TX, June 2014. MSMR 2014; 21:2-6. [PMID: 25162496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Although naturally occurring smallpox virus was officially declared eradicated in 1980, concern for biological warfare prompted the U.S. Government in 2002 to recommend smallpox vaccination for select individuals. Vaccinia, the smallpox vaccine virus, is administered into the skin, typically on the upper arm, where the virus remains viable and infectious until the scab falls off and the epidermis is fully intact - typically 2-4 weeks. Adverse events following smallpox vaccination may occur in the vaccinee, in individuals who have contact with the vaccinee (i.e., secondary transmission), or in individuals who have contact with the vaccinee's contact (i.e., tertiary transmission). In June 2014 at Joint Base San Antonio-Lackland, TX, two cases of inadvertent inoculation of vaccinia and one case of a non-viral reaction following vaccination occurred in the security forces training squadron. This includes the first reported case of shaving as the likely source of autoinoculation after contact transmission. This paper describes the diagnosis and treatment of these cases, the outbreak investigation, and steps taken to prevent future transmission.
Collapse
|
10
|
Affiliation(s)
- Deborah A Kroeker
- Department of Pediatrics, University of Kansas School of Medicine-Wichita, 1010 N. Kansas, Wichita, KS 67214-3199, USA
| | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Borges MBJ, Kato SEM, Damaso CRA, Moussatché N, da Silva Freire M, Lambert Passos SR, do Nascimento JP. Accuracy and repeatability of a micro plaque reduction neutralization test for vaccinia antibodies. Biologicals 2007; 36:105-10. [PMID: 17892944 DOI: 10.1016/j.biologicals.2007.07.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Revised: 06/22/2007] [Accepted: 07/02/2007] [Indexed: 10/22/2022] Open
Abstract
The detection of neutralizing antibodies against vaccinia virus is a valuable tool for the investigation of previous smallpox vaccination. Compulsory smallpox vaccination ended in Brazil during the early 1970s, although the vaccine was available until the late 1970s. The threat of smallpox as a biological weapon has called the attention of public health authorities to the need for an evaluation of the immune status of the population. Based on our previous experience with a micro plaque reduction neutralization test (PRNT) for the evaluation of yellow fever immunity, a similar test was developed for the detection and quantification of vaccinia neutralizing antibodies. A cross-sectional study to test the repeatability and validity of plaque reduction neutralization test (PRNT) for vaccinia antibodies was performed in 182 subjects divided into two categories: subjects above 31 years old and the other > or = 35 years old. Cases were subjects considered to have been vaccinated with vaccinia virus if they declared vaccination history or evidenced vaccination marks. The assay is carried out in 96-well plates, provides results within 30 h, is easily performed, has good sensitivity (92.7%) and specificity (90.8), excellent repeatability (ICC 0.89 (0.88; 0.92)) and is thus suitable for use in mass screening of a population's antibody levels.
Collapse
Affiliation(s)
- Maria Beatriz J Borges
- Vice-diretoria de Desenvolvimento Tecnológico, Bio-Manguinhos/FIOCRUZ, Avenida Brasil 4365, Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil.
| | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Centers for Disease Control and Prevention (CDC). Household transmission of vaccinia virus from contact with a military smallpox vaccinee--Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:478-81. [PMID: 17510612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
On March 7, 2007, the Chicago Department of Public Health and the University of Chicago Pediatric Infectious Disease Service and Infection Control Program notified CDC of a child with presumed eczema vaccinatum (EV), a life-threatening complication of vaccinia virus infection. This is the first reported EV case in the United States since 1988. This report summarizes the epidemiologic and environmental investigations conducted by local, state, and federal public health authorities in Illinois and Indiana to determine the source of exposure and to identify and monitor other persons at risk for vaccinia virus infection. This case highlights the need for clinicians to maintain a high index of suspicion when evaluating recently vaccinated patients and their family members with vesiculopustular rash.
Collapse
|
15
|
Centers for Disease Control and Prevention (CDC). Vulvar vaccinia infection after sexual contact with a military smallpox vaccinee--Alaska, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:417-9. [PMID: 17476203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
On October 10, 2006, an otherwise healthy woman visited a public health clinic in Alaska after vaginal tears that she had first experienced 10 days before became increasingly painful. The patient reported having a new male sex partner during September 22-October 1, 2006. A viral swab specimen from a labial lesion of the woman was submitted to the Alaska State Virology Laboratory (ASVL) for viral culture. The viral isolate could not be identified initially and subsequently was sent to CDC on January 9, 2007, where the isolate was identified as a vaccine-strain vaccinia virus. After vaccinia was identified, investigators interviewed the woman more closely and learned that her new sex partner was a male U.S. military service member stationed at a local military base. Further investigation determined that the service member had been vaccinated for smallpox 3 days before beginning his relationship with the woman. This report describes the clinical evaluation of the woman and laboratory testing performed to identify the isolate. Health-care providers should be aware of the possibility of vaccinia infection in persons with clinically compatible genital lesions who have had recent contact with smallpox vaccinees.
Collapse
|
16
|
de Souza Trindade G, Drumond BP, Guedes MIMC, Leite JA, Mota BEF, Campos MA, da Fonseca FG, Nogueira ML, Lobato ZIP, Bonjardim CA, Ferreira PCP, Kroon EG. Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals. J Clin Microbiol 2007; 45:1370-2. [PMID: 17287326 PMCID: PMC1865848 DOI: 10.1128/jcm.00920-06] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Bovine vaccinia virus outbreaks have been occurring in different regions of Brazil. We report here the time course of natural human infection by vaccinia virus and describe important clinical and epidemiological aspects of this zoonotic infection. The diagnosis of vaccinia virus infection was based on clinical, serological, and molecular procedures.
Collapse
Affiliation(s)
- Giliane de Souza Trindade
- Laboratório de Vírus, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais. Av. Antônio Carlos, 6627, Caixa Postal 486, CEP 31270-901, Belo Horizonte, MG, Brazil
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Brauner SC, Pavan-Langston D. Smallpox, Vaccinia, and the Eye. Clin Ophthalmol 2006; 46:11-25. [PMID: 16770151 DOI: 10.1097/00004397-200604620-00004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Affiliation(s)
- Stacey C Brauner
- Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA
| | | |
Collapse
|
18
|
Lewis FMT, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis 2006; 12:134-7. [PMID: 16494730 PMCID: PMC3291406 DOI: 10.3201/eid1201.051126] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We report a case of ocular vaccinia infection in an unvaccinated laboratory worker. The patient was infected by a unique strain used in an experiment performed partly outside a biosafety cabinet. Vaccination should continue to be recommended, but laboratories with unvaccinated workers should also implement more stringent biosafety practices.
Collapse
Affiliation(s)
- Felicia M T Lewis
- Philadelphia Department of Public Health, Philadelphia, Pennsylvania 19146, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Auckland C, Cowlishaw A, Morgan D, Miller E. Reactions to small pox vaccine in naïve and previously-vaccinated individuals. Vaccine 2005; 23:4185-7. [PMID: 15916840 DOI: 10.1016/j.vaccine.2004.10.052] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2004] [Accepted: 10/22/2004] [Indexed: 10/25/2022]
Abstract
Two hundred health care workers in England and Wales were vaccinated with the Lister/Elstree strain of the vaccinia virus, and completed health diaries for 21 days or until the lesion had scabbed over. Pain and temperature were measured daily, and all other symptoms recorded freehand by the vaccinee. One hundred and forty two (71%) vaccinees reported pain, of which 25% considered it to be moderate or severe; 32 vaccinees (16%) recorded a temperature of >37.7 degrees C, two of which exceeded 39 degrees C. Other, mainly trivial, adverse events were common; itch was reported in 72%, erythema in 27%, axillary pain or lymphadenopathy in 38%, malaise or flu-like symptoms in 40% and headache in 23%. The incidences of minor adverse events were lower in re-vaccinees, compared with naïve vaccine recipients, significantly so in the case of erythema and general malaise (p=0.001 and 0.006, respectively), perhaps reflecting pre-existing immunity. Major adverse events occurred in two vaccinees (hospital admission, one with cellulitis and one with headache and possible encephalitis), and a further five were treated with antibiotics for local cellulitis. This is the first study to report results derived from active follow-up by diaries in recipients of the Lister/Elstree strain of vaccinia, and to document reductions in trivial adverse events in re-vaccinees.
Collapse
Affiliation(s)
- Cressida Auckland
- Immunisation Department, Centre for Infections, Health Protection Agency, 61, Colindale Avenue, London, NW9 5EQ, UK.
| | | | | | | |
Collapse
|
20
|
Egan C, Kelly CD, Rush-Wilson K, Davis SW, Samsonoff WA, Pfeiffer H, Miller J, Taylor J, Cirino NM. Laboratory-confirmed transmission of vaccinia virus infection through sexual contact with a military vaccinee. J Clin Microbiol 2005; 42:5409-11. [PMID: 15528758 PMCID: PMC525226 DOI: 10.1128/jcm.42.11.5409-5411.2004] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A laboratory-confirmed, inadvertent transmission of vaccinia virus from an unusual source highlights the importance of epidemiologic tracing, proper biosafety practices in the clinical diagnostic laboratories, and educating clinicians and laboratorians to potential bioterrorism-initiated outbreaks as well as look-alike disease discrimination.
Collapse
Affiliation(s)
- Christina Egan
- Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Leparc-Goffart I, Poirier B, Garin D, Tissier MH, Fuchs F, Crance JM. Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J Clin Virol 2005; 32:47-52. [PMID: 15572006 DOI: 10.1016/j.jcv.2004.07.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2004] [Accepted: 07/16/2004] [Indexed: 10/26/2022]
Abstract
The possibility of mass population vaccination with smallpox vaccine implies the development of anti-vaccinia immunoglobulins for the treatment of severe side effects following vaccination. We have chosen to develop and validate the "gold standard method" (plaque reduction neutralization assay) to titrate neutralizing anti-vaccinia antibodies in two different French laboratories belonging to the Department of Defense (CRSSA) and to the French Health Products Safety Agency (Afssaps). The results of precision, linearity and accuracy of the method led to consider the method as validated. In parallel, we have prepared and lyophilized a pool of anti-vaccinia plasma samples issued from a unique donor and qualified this preparation versus the first British standard to use it as an in-house standard with a titer of 25 international units (IU). This work will allow to titrate, in IU, sera from vaccinated persons in order (i) to titrate purified anti-vaccinia immunoglobulin preparations for vaccine severe side effect treatments; (ii) to investigate the level of neutralizing antibodies in the general population; and (iii) to investigate clinical trials of new generation smallpox vaccines. In the future, this will allow comparability of studies on either smallpox vaccines or on the serological status of the population.
Collapse
|
22
|
Nagasse-Sugahara TK, Kisielius JJ, Ueda-Ito M, Curti SP, Figueiredo CA, Cruz AS, Silva MMJ, Ramos CH, Silva MCC, Sakurai T, Salles-Gomes LF. Human vaccinia-like virus outbreaks in São Paulo and Goiás States, Brazil: virus detection, isolation and identification. Rev Inst Med Trop Sao Paulo 2004; 46:315-22. [PMID: 15654477 DOI: 10.1590/s0036-46652004000600004] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Since October 2001, the Adolfo Lutz Institute has been receiving vesicular fluids and scab specimens of patients from Paraíba Valley region in the São Paulo and Minas Gerais States and from São Patricio Valley, in the Goiás State. Epidemiological data suggested that the outbreaks were caused by Cowpox virus or Vaccinia virus. Most of the patients are dairy milkers that had vesiculo-pustular lesions on the hands, arms, forearms, and some of them, on the face. Virus particles with orthopoxvirus morphology were detected by direct electron microscopy (DEM) in samples of 49 (66.21%) patients of a total of 74 analyzed. Viruses were isolated in Vero cell culture and on chorioallantoic membrane (CAM) of embryonated chicken eggs. Among 21 samples submitted to PCR using primers for hemagglutinin (HA) gene, 19 were positive. Restriction digestion with TaqI resulted in four characteristic Vaccinia virus fragments. HA nucleotide sequences showed 99.9% similarity with Cantagalo virus, described as a strain of Vaccinia virus. The only difference observed was the substitution of one nucleotide in the position 616 leading to change in one amino acid of the protein in the position 206. The phylogenetic analysis showed that the isolates clustered together with Cantagalo virus, other Vaccinia strains and Rabbitpox virus.
Collapse
Affiliation(s)
- Teresa Keico Nagasse-Sugahara
- Seção de Microscopia Eletrônica, Laboratório de Biologia Molecular, Instituto Adolfo Lutz, Av. Dr. Arnaldo 355, 01246-902, São Paulo, SP, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Fillmore GL, Ward TP, Bower KS, Dudenhoefer EJ, Grabenstein JD, Berry GK, Madigan WP. Ocular complications in the Department of Defense Smallpox Vaccination Program. Ophthalmology 2004; 111:2086-93. [PMID: 15522376 DOI: 10.1016/j.ophtha.2004.04.027] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2003] [Accepted: 04/06/2004] [Indexed: 10/26/2022] Open
Abstract
OBJECTIVE The purpose of this case series was to present an overview of the nature and frequency of ocular complications in the Department of Defense (DoD) Smallpox Vaccination Program. DESIGN Retrospective, noncomparative case series. PARTICIPANTS The authors retrospectively evaluated data collected on individuals with an ophthalmologic complaint after receiving smallpox vaccination or after contact with a recently immunized individual. The vaccinee and contact cases occurred secondary to inoculations given between December 13, 2002 and May 28, 2003 as part of the DoD Smallpox Vaccination Program. METHODS Data were collected primarily from reports to military headquarters or to the Vaccine Adverse Event Reporting System and individual medical records. MAIN OUTCOME MEASURES The incidence, types, and timing of ocular complications were evaluated. Diagnostic and treatment considerations also were reviewed. RESULTS Between December 13, 2002 and May 28, 2003, 450,293 smallpox vaccinations were given. We identified 16 confirmed or probable cases of ocular vaccinia, with an incidence of 3.6 per 100,000 inoculations. Of these cases, 12 (75%) were seen in the vaccinees, and 4 (25%) in close contacts. Of the 12 self-inoculation cases, 7 (58.3%) were seen in individuals receiving the vaccine for the first time (primary vaccination), and 3 (25.0%) were seen in individuals previously vaccinated (revaccination); the vaccination status in 2 cases was unknown. Clinical manifestations included lid pustules, blepharitis, periorbital cellulitis, conjunctivitis, conjunctival ulcers, conjunctival membranes, limbal pustules, corneal infiltrates, and iritis, with onset of symptoms 3 to 24 days after inoculation or contact. Five of 9 tested cases were culture or polymerase chain reaction positive for vaccinia. Treatment for most cases was topical trifluridine 1% (Viroptic; King Pharmaceuticals, Inc., Bristol, TN). Vaccinia immune globulin was used in 1 case. In all patients, recovery occurred without significant visual sequelae. CONCLUSIONS When compared with historical data on the ocular complications of smallpox vaccination, the incidence of ocular complications during the DoD Smallpox Vaccination program has been low. In addition, the severity of disease seems to be less than during other vaccination periods. These findings perhaps are the result of improved screening of vaccinees, prevaccination counseling, postvaccination wound care, and the suggested efficacy of trifluridine in the treatment of ocular vaccinia.
Collapse
Affiliation(s)
- Gary L Fillmore
- Ophthalmology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
A 26-year-old male medical technician who received the smallpox (vaccinia) vaccination developed a clinical case of myocarditis 11 days after vaccination. The medical literature has little information on this complication of vaccination. The individual was admitted for evaluation and pain control. At discharge, he appeared to have had no long-term effects and has returned to duty.
Collapse
Affiliation(s)
- Bruce R Guerdan
- 171st Medical Group, Pittsburgh International Airport, Pittsburgh, PA, USA
| | | |
Collapse
|
25
|
Abstract
This case report demonstrates the clinical progression of a case of lesions consistent with generalized vaccinia after primary vaccination in an otherwise healthy adult. The photographs document the appearance and natural course. The progression of the lesions is discussed, documenting the natural progression of the disease. This case report includes photographs of the oral lesions consistent with generalized vaccinia. Oral generalized vaccinia lesions are not well documented in the current medical literature.
Collapse
Affiliation(s)
- William A Gibson
- SAUSHEC Emergency Medicine Residency Program, Wilford Hall Medical Center, Lackland AFB, Texas, USA
| | | |
Collapse
|
26
|
Abstract
BACKGROUND Complications following vaccination with vaccinia virus have been well described but are not commonly observed. The use of vaccinia as a tool in molecular biology, in the development of therapeutics, and the anticipated increase of vaccinations in the general population due to the threat of bioterrorism have created a renewed awareness of the post-vaccination complications and the consequent need for clinical and laboratory diagnosis. OBJECTIVES To report the clinical presentation and subsequent diagnosis of generalized vaccinia that resulted from a laboratory accident in an unvaccinated subject. STUDY DESIGN The patient was seen by a local infectious disease's specialist and evaluated clinically and with laboratory support relative to a differential diagnosis. RESULTS Careful assessment of the patient's history, an evaluation of the workplace, and the elimination of likely microbial etiologies led to the diagnosis of generalized vaccinia. Laboratory confirmation was obtained by use of electron microscopy (EM) to observe poxvirus particles in infected cell cultures. CONCLUSIONS Exposure to vaccinia virus should raise the index of suspicion for patients with skin lesions. Rapid diagnosis may be accomplished by direct examination of lesion material by EM. The virus also readily replicates in commonly available cell cultures and in the absence of immune reagents, typical poxvirus particles may be observed in the infected cells by EM.
Collapse
Affiliation(s)
- Clifford G Wlodaver
- Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | | | | |
Collapse
|
27
|
Abstract
In December 2002, the federal government began a program to immunize approximately 500000 civilian public health and health care workers with smallpox (vaccinia) vaccine as a part of our pre-event defense against bioterrorism. First responders will likely follow, and the general US population might be offered vaccination in the next 1 to 2 years. Recent reports that suggest the possible association of the vaccine to adverse cardiac events (including deaths), liability concerns for hospitals, and the availability of compensation for workers with vaccine complications have significantly reduced voluntary participation. Vaccinees might experience robust primary takes or serious adverse events, including viral or even bacterial cellulitides, encephalitis, progressive skin destruction, and other life-threatening complications. With the increasing prevalence of immune suppression from both diseases and immunosuppressive medications, complications might be seen in higher frequency than previously reported. Emergency medicine providers and staff must become familiar with clinical presentations and management of vaccine complications. In addition, policies and procedures must be developed to prevent unimmunized providers from inadvertently contacting the active vaccination sites of their patients and, if the providers themselves have active vaccination sites, to protect their patients and their own families.
Collapse
Affiliation(s)
- Craig D Thorne
- Occupational and Environmental Health Program, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
| | | | | | | |
Collapse
|
28
|
Peev M, Weber SG, Daum RS, Garcia-Houchinss S, Marcinak J. Disseminated vaccinia false alarm. Pediatr Infect Dis J 2003; 22:925-6. [PMID: 14579813 DOI: 10.1097/01.inf.0000091391.14809.3d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We report the case of a 6-year-old girl who presented in December 2002 with fever and a vesicular rash. Initially she was diagnosed with Stevens-Johnson syndrome. The differential diagnosis was expanded, however, when an exposure to a person who was believed to be vaccinated recently against smallpox was revealed. We describe the sequence of events that ensued and the workup for a possible case of disseminated virus.
Collapse
Affiliation(s)
- Milan Peev
- Department of Pediatrics, University of Chicago, IL, USA
| | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- John M Besser
- Public Health Laboratory, Minnesota Department of Public Health, Minneapolis, MN 55414, USA
| | | | | |
Collapse
|
30
|
Maurer DM, Harrington B, Lane JM. Smallpox vaccine: contraindications, administration, and adverse reactions. Am Fam Physician 2003; 68:889-96. [PMID: 13678138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2023]
Abstract
Since the terrorist attacks of September 11, 2001, and the anthrax exposures in the following weeks, concern that smallpox could be used as a biologic weapon has increased. Public health departments and the U.S. military have begun the process of vaccinating soldiers and civilian first-responders. Smallpox vaccination carries some serious risks: approximately one in 1 million primary vaccinees and one in 4 million revaccinees will die from adverse vaccine reactions. The most serious side effects of smallpox vaccine include progressive vaccinia, postvaccinial central nervous system disease, and eczema vaccinatum. Some of these reactions can be treated with vaccinia immune globulin or cidofovir. Proper patient screening and site care are essential. Family physicians must learn to screen potential vaccinees for contraindications (e.g., immunodeficiency, immunosuppression, certain skin and eye diseases, pregnancy, lactation, allergy to the vaccine or its components, moderate or severe intercurrent illness) and to treat vaccine-associated adverse reactions.
Collapse
Affiliation(s)
- Douglas M Maurer
- Family Practice Residency Program, Darnall Army Community Hospital, Ft. Hood, Texas 76544, USA.
| | | | | |
Collapse
|
31
|
Abstract
PURPOSE To describe the ocular complications of smallpox vaccination and to discuss potential therapeutic options. DESIGN Review of pertinent medical literature and recent treatment recommendations of the Centers for Disease Control and Prevention. RESULTS After immunization against smallpox, vaccinia infection of the eyelid, conjunctiva, or ocular surface can result from accidental autoinoculation from a vaccination site before scab formation or from contact with a recently vaccinated individual. While uncommon, corneal involvement can lead to stromal opacification and scarring. Clinical findings of ocular and periocular vaccinia must be differentiated from those produced by other pathogens such as molluscum contagiosum, herpes simplex, varicella zoster, and acanthamoeba infections. Clinical diagnosis can be confirmed by electron microscopy to identify the presence of orthopoxvirus, as well as by virologic culture, polymerase chain reaction, and/or restriction endonuclease analysis of viral isolates. CONCLUSIONS While the majority of ocular complications of smallpox vaccination in immunocompetent patients are self-limiting, selective cases may require treatment with trifluridine drops, topical corticosteroids and vaccinia immune globulin (VIG). Vaccinia virus does not appear to be sensitive to acyclovir. Specific treatment recommendations are outlined for the spectrum of ocular manifestations.
Collapse
Affiliation(s)
- Jay S Pepose
- Pepose Vision Institute, Chesterfield, Missouri 63017, USA
| | | | | | | |
Collapse
|
32
|
Moussatché N, Tuyama M, Kato SEM, Castro APV, Njaine B, Peralta RH, Peralta JM, Damaso CRA, Barroso PF. Accidental infection of laboratory worker with vaccinia virus. Emerg Infect Dis 2003; 9:724-6. [PMID: 12781015 PMCID: PMC3000149 DOI: 10.3201/eid0906.020732] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We report the accidental needlestick inoculation of a laboratory worker with vaccinia virus. Although the patient had previously been vaccinated against smallpox, severe lesions appeared on the fingers. Western blot and polymerase chain reaction-restriction fragment length polymorphism were used to analyze the virus recovered from the lesions. The vaccinia virus-specific immunoglobulin G levels were measured by enzyme-linked immunosorbent assay. Our study supports the need for vaccination for laboratory workers that routinely handle orthopoxvirus.
Collapse
Affiliation(s)
- Nissin Moussatché
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro Brazil.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
From the Centers for Disease Control and Prevention. Smallpox vaccine adverse events among civilians--United States, February 18-24, 2003. JAMA 2003; 289:1627-8. [PMID: 12672719 DOI: 10.1001/jama.289.13.1627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
34
|
From the Center of Disease Control and Prevention. Smallpox vaccine adverse events among civilians--United States, January 24-February 18, 2003. JAMA 2003; 289:1497-8. [PMID: 12672751 DOI: 10.1001/jama.289.12.1497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
35
|
Mempel M, Isa G, Klugbauer N, Meyer H, Wildi G, Ring J, Hofmann F, Hofmann H. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J Invest Dermatol 2003; 120:356-8. [PMID: 12603846 DOI: 10.1046/j.1523-1747.2003.12074.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Handling of Vaccinia virus represents a risk for laboratory-acquired infections, especially in individuals without completed vaccination. We report the case of a Vaccinia infection in a previously vaccinated researcher working with various genetically modified strains. We could confirm the infection by electron microscopy, positive cell culture, virus-specific PCR, sequence analysis, and viral neutralization test. The isolated virus carried a functionally inactivated cytohesin-1 gene of human origin, which had been shown to impair leukocyte adhesion by interacting with the LFA/ICAM-1 axis. The immunomodulating nature of the inserted construct might thus have added to the infectivity of the virus. We emphasize on the necessity of Vaccinia vaccination in laboratory staff working in the field.
Collapse
Affiliation(s)
- Martin Mempel
- Department of Dermatology and Allergy, Biederstein, Technical University Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Centers for Disease Control and Prevention (CDC). Smallpox vaccine adverse events among civilians--United States, February 18-24, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:156-7. [PMID: 12625500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
During the civilian smallpox vaccination program, CDC and state health departments are conducting surveillance for vaccine-associated adverse events. In the first stage of the program, active surveillance is being conducted for potentially life-threatening, moderate-to-severe, and other serious adverse events and for vaccinia transmission to contacts of vaccinees (Table). Nonserious events are reported through passive surveillance and are expected to be underreported. This report summarizes smallpox vaccine adverse events reported among civilians vaccinated as of February 21, 2003, and received by CDC from the Vaccine Adverse Event Reporting System (VAERS) as of February 24.
Collapse
|
37
|
Centers for Disease Control and Prevention (CDC). Smallpox vaccine adverse events among civilians--United States, January 24-February 18, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:136. [PMID: 12617539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
During the civilian smallpox vaccination program, CDC and state health departments are conducting surveillance for vaccine-associated adverse events. In the first stage of the program, active surveillance is being conducted for potentially life-threatening, moderate-to-severe, and other serious adverse events and for vaccinia transmission to contacts of vaccinees (Table). Nonserious events are reported via passive surveillance and are expected to be underreported. This report summarizes smallpox vaccine adverse events reported among civilians vaccinated as of February 14, 2003, and received by CDC from the Vaccine Adverse Event Reporting System (VAERS) as of February 18.
Collapse
|
38
|
Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003; 52:1-28. [PMID: 12617510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023] Open
Abstract
The guidance in this report is for evaluation and treatment of patients with complications from smallpox vaccination in the preoutbreak setting. Information is also included related to reporting adverse events and seeking specialized consultation and therapies for these events. The frequencies of smallpox vaccine-associated adverse events were identified in studies of the 1960s. Because of the unknown prevalence of risk factors among today's population, precise predictions of adverse reaction rates after smallpox vaccination are unavailable. The majority of adverse events are minor, but the less-frequent serious adverse reactions require immediate evaluation for diagnosis and treatment. Agents for treatment of certain vaccine-associated severe adverse reactions are vaccinia immune globulin (VIG), the first-line therapy, and cidofovir, the second-line therapy. These agents will be available under Investigational New Drug (IND) protocols from CDC and the U.S. Department of Defense (DoD). Smallpox vaccination in the preoutbreak setting is contraindicated for persons who have the following conditions or have a close contact with the following conditions: 1) a history of atopic dermatitis (commonly referred to as eczema), irrespective of disease severity or activity; 2) active acute, chronic, or exfoliative skin conditions that disrupt the epidermis; 3) pregnant women or women who desire to become pregnant in the 28 days after vaccination; and 4) persons who are immunocompromised as a result of human immunodeficiency virus or acquired immunodeficiency syndrome, autoimmune conditions, cancer, radiation treatment, immunosuppressive medications, or other immunodeficiencies. Additional contraindications that apply only to vaccination candidates but do not include their close contacts are persons with smallpox vaccine-component allergies, women who are breastfeeding, those taking topical ocular steroid medications, those with moderate-to-severe intercurrent illness, and persons aged < 18 years. In addition, history of Darier disease is a contraindication in a potential vaccinee and a contraindication if a household contact has active disease. In the event of a smallpox outbreak, outbreak-specific guidance will be disseminated by CDC regarding populations to be vaccinated and specific contraindications to vaccination. Vaccinia can be transmitted from a vaccinee's unhealed vaccination site to other persons by close contact and can lead to the same adverse events as in the vaccinee. To avoid transmission of vaccinia virus (found in the smallpox vaccine) from vaccinees to their close contacts, vaccinees should wash their hands with warm soapy water or hand rubs containing > or = 60% alcohol immediately after they touch their vaccination site or change their vaccination site bandages. Used bandages should be placed in sealed plastic bags and can be disposed of in household trash. Smallpox vaccine adverse reactions are diagnosed on the basis of clinical examination and history, and certain reactions can be managed by observation and supportive care. Adverse reactions that are usually self-limited include fever, headache, fatigue, myalgia, chills, local skin reactions, nonspecific rashes, erythema multiforme, lymphadenopathy, and pain at the vaccination site. Other reactions are most often diagnosed through a complete history and physical and might require additional therapies (e.g., VIG, a first-line therapy and cidofovir, a second-line therapy). Adverse reactions that might require further evaluation or therapy include inadvertent inoculation, generalized vaccinia (GV), eczema vaccinatum (EV), progressive vaccinia (PV), postvaccinial central nervous system disease, and fetal vaccinia. Inadvertent inoculation occurs when vaccinia virus is transferred from a vaccination site to a second location on the vaccinee or to a close contact. Usually, this condition is self-limited and no additional care is needed. Inoculations of the eye and eyelid require evaluation by an ophthalmologist and might require therapy with topical antiviral or antibacterial medications, VIG, or topical steroids. GV is characterized by a disseminated maculopapular or vesicular rash, frequently on an erythematous base, which usually occurs 6-9 days after first-time vaccination. This condition is usually self-limited and benign, although treatment with VIG might be required when the patient is systemically ill or found to have an underlying immunocompromising condition. Infection-control precautions should be used to prevent secondary transmission and nosocomial infection. EV occurs among persons with a history of atopic dermatitis (eczema), irrespective of disease severity or activity, and is a localized or generalized papular, vesicular, or pustular rash, which can occur anywhere on the body, with a predilection for areas of previous atopic dermatitis lesions. Patients with EV are often systemically ill and usually require VIG. Infection-control precautions should be used to prevent secondary transmission and nosocomial infection. PV is a rare, severe, and often fatal complication among persons with immunodeficiencies, characterized by painless progressive necrosis at the vaccination site with or without metastases to distant sites (e.g., skin, bones, and other viscera). This disease carries a high mortality rate, and management of PV should include aggressive therapy with VIG, intensive monitoring, and tertiary-level supportive care. Anecdotal experience suggests that, despite treatment with VIG, persons with cell-mediated immune deficits have a poorer prognosis than those with humoral deficits. Infection-control precautions should be used to prevent secondary transmission and nosocomial infection. Central nervous system disease, which includes postvaccinial encephalopathy (PVE) and postvaccinial encephalomyelitis (or encephalitis) (PVEM), occur after smallpox vaccination. PVE is most common among infants aged < 12 months. Clinical symptoms of central nervous system disease indicate cerebral or cerebellar dysfunction with headache, fever, vomiting, altered mental status, lethargy, seizures, and coma. PVE and PVEM are not believed to be a result of replicating vaccinia virus and are diagnoses of exclusion. Although no specific therapy exists for PVE or PVEM, supportive care, anticonvulsants, and intensive care might be required. Fetal vaccinia, resulting from vaccinial transmission from mother to fetus, is a rare, but serious, complication of smallpox vaccination during pregnancy or shortly before conception. It is manifested by skin lesions and organ involvement, and often results in fetal or neonatal death. No known reliable intrauterine diagnostic test is available to confirm fetal infection. Given the rarity of congenital vaccinia among live-born infants, vaccination during pregnancy should not ordinarily be a reason to consider termination of pregnancy. No known indication exists for routine, prophylactic use of VIG in an unintentionally vaccinated pregnant woman; however, VIG should not be withheld if a pregnant woman develops a condition where VIG is needed. Other less-common adverse events after smallpox vaccination have been reported to occur in temporal association with smallpox vaccination, but causality has not been established. Prophylactic treatment with VIG is not recommended for persons or close contacts with contraindications to smallpox vaccination who are inadvertently inoculated or exposed. These persons should be followed closely for early recognition of adverse reactions that might develop, and clinicians are encouraged to enroll these persons in the CDC registry by calling the Clinician Information Line at 877-554-4625. To request clinical consultation and IND therapies for vaccinia-related adverse reactions for civilians, contact your state health department or CDC's Clinician Information Line (877-554-4625). Clinical evaluation tools are available at http.//www.bt.cdc.gov/agent/smallpox/vaccination/clineval. Clinical specimen-collection guidance is available at http://www.bt.cdc.gov/agent/smallpox/vaccination/vaccinia-specimen-collection.asp. Physicians at military medical facilities can request VIG or cidofovir by calling the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at 301-619-2257 or 888-USA-RIID.
Collapse
MESH Headings
- Adolescent
- Adult
- Adverse Drug Reaction Reporting Systems
- Aged
- Antiviral Agents/administration & dosage
- Antiviral Agents/adverse effects
- Antiviral Agents/therapeutic use
- Central Nervous System Diseases/diagnosis
- Central Nervous System Diseases/etiology
- Central Nervous System Diseases/therapy
- Child
- Child, Preschool
- Cidofovir
- Contraindications
- Cross Infection/prevention & control
- Cytosine/administration & dosage
- Cytosine/adverse effects
- Cytosine/analogs & derivatives
- Cytosine/therapeutic use
- Disease Transmission, Infectious/prevention & control
- Drugs, Investigational/administration & dosage
- Drugs, Investigational/adverse effects
- Drugs, Investigational/therapeutic use
- Eye Infections/diagnosis
- Eye Infections/etiology
- Eye Infections/therapy
- Female
- Fetal Diseases
- Humans
- Hypersensitivity/diagnosis
- Hypersensitivity/etiology
- Hypersensitivity/therapy
- Immunocompromised Host
- Immunoglobulins, Intravenous/administration & dosage
- Immunoglobulins, Intravenous/adverse effects
- Immunoglobulins, Intravenous/therapeutic use
- Immunologic Tests
- Infant
- Infection Control
- Infectious Disease Transmission, Vertical
- Male
- Middle Aged
- Organophosphonates
- Organophosphorus Compounds/administration & dosage
- Organophosphorus Compounds/adverse effects
- Organophosphorus Compounds/therapeutic use
- Pregnancy
- Risk Factors
- Skin Diseases, Eczematous/diagnosis
- Skin Diseases, Eczematous/etiology
- Skin Diseases, Eczematous/therapy
- Skin Diseases, Vesiculobullous/diagnosis
- Skin Diseases, Vesiculobullous/etiology
- Skin Diseases, Vesiculobullous/therapy
- Smallpox Vaccine/adverse effects
- Vaccination/adverse effects
- Vaccinia/diagnosis
- Vaccinia/immunology
- Vaccinia/prevention & control
- Vaccinia/transmission
Collapse
Affiliation(s)
- Joanne Cono
- Bioterrorism Preparedness and Response Program, National Center for Infectious Diseases, USA
| | | | | |
Collapse
|
39
|
Onishchenko GG, Markov VI, Ustiushin VN, Borisevich SV, Kuznetsova GI, Loginova SI, Berezhnoĭ AM, Vasil'ev NT, Maksimov VA, Makhlaĭ AA. [Isolation and identification of the smallpox virus which caused iatrogenic vaccinia in children in the city of Vladivostok]. Zh Mikrobiol Epidemiol Immunobiol 2001:40-5. [PMID: 11548257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
The comparative study of the specimens of the morphological elements of exanthema obtained from 8 children with the clinical diagnosis of secondary exogenic vaccinia, dried smallpox vaccine and the cultures of other orthopoxviruses (rabbit pox, monkey pox and buffalo pox viruses) was made. The isolation and identification of the causative agents from the specimens was carried out with the use of modern virological, electron microscopic and molecular methods. The study proved the fact that 8 children had orthopoxvirus infection with its causative agent identified as vaccinia virus.
Collapse
|
40
|
ANGULO JJ, de SALLES-GOMES L, CUBAS DOS SANTOS C, BASSOI ON. Observations on vaccinial eruptions and differential diagnosis of generalized vacinia. Postgrad Med J 1998; 38:145-9. [PMID: 13861632 PMCID: PMC2482398 DOI: 10.1136/pgmj.38.437.145] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Abstract
A patient who used contact lenses and had a history of blunt trauma developed vaccinia keratouveitis after accidental ocular autoinoculation from a recent vaccination site. Corneal and conjunctival cultures were taken for bacteria, fungi, Acanthamoeba, and viruses. Viral-like cytopathic effects became evident in tissue culture within three days. Immunofluorescence studies were negative for varicella-zoster virus, herpes simplex virus, adenovirus, measles, mumps, parainfluenza, and influenza. Pox viral particles were identified in the infected tissue cultures by electron microscopy. The Hind III restriction endonuclease profile of the viral DNA isolate was similar to the Lister strain of vaccinia virus. Ocular vaccinia may manifest as a masquerade syndrome and may mimic signs of herpes simplex virus, varicella-zoster virus, and Acanthamoeba infection. Although vaccination with vaccinia is currently limited to a few populations throughout the world, vaccinia must still be considered in the differential diagnosis of infectious keratouveitis.
Collapse
Affiliation(s)
- S F Lee
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri 63110
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Pfeiff B, Pullmann H, Eis-Hübinger AM, Gerritzen A, Schneweis KE, Mayr A. [Lethal animal pox virus infection in an atopic patient simulating variola vera]. Hautarzt 1991; 42:293-7. [PMID: 1651909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
An 18-year-old patient requiring steroid treatment for severe bronchial asthma and with atopic dermatitis acquired a cowpox-like virus infection clinically similar to smallpox from a domestic cat as carrier. In spite of intensive care, with controlled pressure breathing and the last available vaccinia hyperimmunoglobulin, the patient died of pulmonary embolism although viral spread had ceased some days before.
Collapse
Affiliation(s)
- B Pfeiff
- Dermatologische Abteilung, Krankenhäuser des Märkischen Kreises, Lüdenscheid
| | | | | | | | | | | |
Collapse
|
43
|
Klingebiel T, Vallbracht A, Döller G, Stierhof YD, Gerth HJ, Glashauser E, Herzau V. A severe human cowpox infection in south Germany. Pediatr Infect Dis J 1988; 7:883-5. [PMID: 3062564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- T Klingebiel
- Department of Pediatrics, Eberhard-Karls University, Tübingen, Federal Republic of Germany
| | | | | | | | | | | | | |
Collapse
|
44
|
Marennnikova SS, Zhukova OA, Manenkova GM, Ianova NN. [Laboratory-confirmed case of human infection with ratpox (cowpox)]. Zh Mikrobiol Epidemiol Immunobiol 1988:30-2. [PMID: 3176779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The present work describes a case of human disease resulting from the bite of a white rat and caused by a biological variant of cowpox virus. The isolates obtained from the sick man and the white rats which had been the source of this infection proved to be identical and did not differ from the biological variants of cowpox virus, isolated earlier from white rats and carnivorous animals of the family Felidae. Thus, the possibility of ratpox (cowpox) transmission from sick rodents to man was established.
Collapse
|
45
|
Landthaler M, Strasser S, Schmoeckel C. [Vaccinia inoculata]. Hautarzt 1988; 39:322-3. [PMID: 3403269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A case of vaccinia inoculata in a 58-year-old woman with a bullous lesion on the left cheek is reported. The diagnosis was established by reference to her professional background and by electron microscopy (negative staining method).
Collapse
Affiliation(s)
- M Landthaler
- Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München
| | | | | |
Collapse
|
46
|
Abstract
Since October 1982 three cases of cowpox infection of the cat have been presented at a veterinary practice. The disease began as a focal dermatitis on the face or paws which spread after several days to the rest of the body. Two weeks after appearing the pocks scabbed over and fell off leaving hairless skin. There were few systemic signs and therapy did not appear to influence the course of the disease. Diagnosis was confirmed by the demonstration of pox virions or inclusion bodies in skin biopsy or scab material using electron microscopy and by isolation of cowpox virus in chick embryos. High antibody titres to cowpox were observed in the sera of two cats.
Collapse
|
47
|
Abstract
Teat lesions affect the dairyman by interfering with the milking process or by increasing the likelihood of intramammary infection. Lesions where the skin is broken are frequently infected. The viral, chemical, environmental, and equipment-induced lesions that lead to ulceration, hemorrhage, and scabbing are all associated with increased intramammary infection; however, this association does not necessarily hold true with the less severe conditions. The dry and flakey skin seen with certain teat dips, lime, or sunburn, the common teat-end callous condition, and the mild, temporary congestion or edema sometimes seen after machine milking usually do not lead to increased intramammary infection. When investigating a problem of increased intramammary infection, other factors should be discussed with the dairyman before suggesting that these conditions are the cause of the problem. Before making a diagnosis of machine-induced lesions, the milking equipment should be carefully inspected and tested. Although the equipment can and frequently does cause lesions, it rarely does so if it is properly set or maintained. Maintenance of inflations, pulsators, vacuum regulators, and vacuum pumps will frequently reveal the source of the problem. In most cases, an equipment malfunction must be quite severe to result in teat injury. Many teat-lesion problems are seasonal in occurrence. The problem will frequently subside in the spring only to reoccur in mid fall. In the midwestern United States, most teat-lesion problems occur from November to April. When investigating a teat-lesion complaint, a large proportion of the herd should be examined.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
48
|
|
49
|
Abstract
The most important viral organisms involving the eye are the DNA viruses herpes simplex, varicella-zoster, cytomegalovirus, adenovirus, and vaccinia virus. All of these agents except CMV may cause acute epithelial infection, sterile trophic ulceration due to basement membrane damage, deep corneal stromal immune reaction, and iritis. Although there are three excellent antiviral drugs commercially available, only HSV and vaccinia virus are highly sensitive to therapy with these antimetabolites; varicella-zoster virus and CMV are equivocally responsive and adenovirus has not been shown to be susceptible to these agents. In selected situations, topical or systemic corticosteroids are useful for managing any associated immune reactions in the eyes, but patients on these drugs should be monitored carefully both for superinfections and for interference with tissue healing that might ultimately threaten the integrity of the globe.
Collapse
|
50
|
Keane JT, James K, Blankenship ML, Pearson RW. Progressive vaccinia associated with combined variable immunodeficiency. Arch Dermatol 1983; 119:404-8. [PMID: 6847220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Progressive vaccinia developed in a previously healthy woman following smallpox vaccination and was successfully treated with vaccinia immune human globulin and methisazone. Immunologic evaluation over the next 4 1/2 years revealed evidence for combined variable immunodeficiency with increased numbers of circulating OKT 8 positive (suppressor-cytotoxic T) cells and the virtual absence of OKT 4 positive (helper-inducer T) cells.
Collapse
|